ABBV · Earnings call · 2026Q3T · Full report

Geographic Market Commentary

AbbVie Inc. · 2026-10-30 · Importance 26 · Surprise 24

Management said the Boey commercial rollout was underway in Europe and Canada, with high patient satisfaction reported in those markets. TrenibotE had European and Canadian approvals, while AbbVie planned submissions in other countries as it gathered information requested by the FDA. For frontline Epkinly use, management emphasized the potential for adoption around the world and noted that reimbursement views on competing Polivy-based regimens vary by country.

Key facts

• AbbVie already has European and Canadian approvals for TrenibotE and is submitting it in other countries.